{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:48:35Z","timestamp":1792068515288,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008519","name":"University of Arkansas for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008519","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008231","name":"Arkansas Biosciences Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008231","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.amepre.2026.108508","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:29:17Z","timestamp":1784244557000},"page":"108508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["State X-Waiver Statutes and Buprenorphine Prescriber Rates After Federal X-Waiver Elimination, 2021\u22122023"],"prefix":"10.1016","volume":"71","author":[{"given":"Filmon","family":"Wolde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley C.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-3705","authenticated-orcid":false,"given":"Mahip","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2042-2174","authenticated-orcid":false,"given":"Laura","family":"Gressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-5149","authenticated-orcid":false,"given":"Chenghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob T.","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7776-6157","authenticated-orcid":false,"given":"Corey J.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.amepre.2026.108508_bib0001","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: an overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"issue":"25","key":"10.1016\/j.amepre.2026.108508_bib0002","doi-asserted-by":"crossref","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: population estimates \u2014 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.amepre.2026.108508_bib0003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3934\/publichealth.2025005","article-title":"Barriers and facilitators to prescribing buprenorphine for treating opioid use disorder among emergency department and other practice setting physicians","volume":"12","author":"Swartz","year":"2025","journal-title":"AIMS Public Health"},{"key":"10.1016\/j.amepre.2026.108508_bib0004","unstructured":"DATA. Waiver for buprenorphine eliminated. MedCentral. https:\/\/www.medcentral.com\/addiction-med\/oud\/data-waiver-for-buprenorphine-eliminated. Updated 2023. Accessed September 13, 2025."},{"issue":"3","key":"10.1016\/j.amepre.2026.108508_bib0005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/08897077231186212","article-title":"Will the end of the X-waiver expand access to buprenorphine treatment? Achieving the full potential of the 2023 Consolidated Appropriations Act","volume":"44","author":"Saloner","year":"2023","journal-title":"Subst Abus"},{"key":"10.1016\/j.amepre.2026.108508_bib0006","unstructured":"X-waiver no longer required to treat opioid use disorder. American College of Emergency Physicians.https:\/\/www.acep.org\/news\/acep-newsroom-articles\/x-waiver-no-longer-required-to-treat-opioid-use-disorder. Updated January 13, 2023. Accessed September 13, 2025."},{"key":"10.1016\/j.amepre.2026.108508_bib0007","unstructured":"Removing the X-waiver to prescribe buprenorphine. Pharmacy. https:\/\/www.pharmacy.umn.edu\/removing-x-waiver-prescribe-buprenorphine. Accessed September 13, 2025."},{"key":"10.1016\/j.amepre.2026.108508_bib0008","unstructured":"Waiver elimination (MAT Act); 2024. SAMHSA. https:\/\/www.samhsa.gov\/substance-use\/treatment\/resources\/mat-act. Updated November 6, 2024. Accessed September 13, 2025."},{"key":"10.1016\/j.amepre.2026.108508_bib0009","article-title":"State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements","volume":"7","author":"Silwal","year":"2023","journal-title":"Drug Alcohol Depend Rep"},{"key":"10.1016\/j.amepre.2026.108508_bib0010","series-title":"Legal barriers to buprenorphine, a vital tool in managing recovery and preventing opioid overdose death","year":"2024"},{"key":"10.1016\/j.amepre.2026.108508_bib0011","unstructured":"About LawAtlas and the Center for Public Health law research. LawAtlas. https:\/\/lawatlas.org\/about. Accessed September 13, 2025."},{"issue":"8","key":"10.1016\/j.amepre.2026.108508_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.25999","article-title":"Buprenorphine prescribing characteristics following relaxation of X-waiver training requirements","volume":"7","author":"Christine","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.amepre.2026.108508_bib0013","article-title":"The effect of federal policy changes on buprenorphine prescribing in Massachusetts","volume":"6","author":"Hayes","year":"2025","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"10.1016\/j.amepre.2026.108508_bib0014","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jclinepi.2018.05.026","article-title":"A methodological framework for model selection in interrupted time series studies","volume":"103","author":"Lopez Bernal","year":"2018","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.amepre.2026.108508_bib0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1536867X1501500208","article-title":"Conducting interrupted time-series analysis for single- and multiple-group comparisons","volume":"15","author":"Linden","year":"2015","journal-title":"Stata J Promot Commun Stat Stata"},{"key":"10.1016\/j.amepre.2026.108508_bib0016","unstructured":"IQVIA PharMetrics Plus for academics. IQVIA.https:\/\/www.iqvia.com\/locations\/united-states\/library\/fact-sheets\/iqvia-pharmetrics-plus-for-academics. Updated September 18, 2024. Accessed September 13, 2025."},{"issue":"9","key":"10.1016\/j.amepre.2026.108508_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35478","article-title":"Association of daily doses of buprenorphine with urgent health care utilization","volume":"7","author":"Axeen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amepre.2026.108508_bib0018","article-title":"Association between buprenorphine adherence for opioid use disorder and clinical events and healthcare spending among older patients","volume":"176","author":"Olateju","year":"2025","journal-title":"J Subst Use Addict Treat"},{"issue":"3","key":"10.1016\/j.amepre.2026.108508_bib0019","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2307\/1913610","article-title":"A Simple, Positive semi-definite, heteroskedasticity and autocorrelation consistent covariance matrix","volume":"55","author":"Newey","year":"1987","journal-title":"Econometrica"},{"key":"10.1016\/j.amepre.2026.108508_bib0020","unstructured":"Clustered covariance matrix estimation for panel data\u2014vcovPL. Robust Covariance Matrix Estimators, Sandwich. https:\/\/sandwich.r-forge.r-project.org\/reference\/vcovPL.html. Accessed April 27, 2026."},{"issue":"16","key":"10.1016\/j.amepre.2026.108508_bib0021","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJMc2312906","article-title":"Buprenorphine dispensing after elimination of the waiver requirement","volume":"390","author":"Chua","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amepre.2026.108508_bib0022","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.mayocpiqo.2024.04.004","article-title":"Trends in the prescribing of buprenorphine for opioid use disorder, 2019\u20132023","volume":"8","author":"Savitz","year":"2024","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.amepre.2026.108508_bib0023","unstructured":"Buprenorphine dispensing rate maps. Overdose prevention. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/buprenorphine-dispensing-maps.html. Updated 2024. Accessed September 25, 2025."},{"key":"10.1016\/j.amepre.2026.108508_bib0024","series-title":"Practice guidelines for the administration of buprenorphine for treating opioid use disorder","year":"2021"},{"key":"10.1016\/j.amepre.2026.108508_bib0025","unstructured":"Newsletter. Kentucky Board of Medical Licensure. https:\/\/kbml.ky.gov\/newsletter\/Pages\/default.aspx?View=2023&Title=Table%20Viewer%20Webpart. Updated 2023. Accessed March 18, 2026."},{"key":"10.1016\/j.amepre.2026.108508_bib0026","unstructured":"Information for medication assisted treatment (MAT) providers in West Virginia. Bureau for Behavioral Health. https:\/\/bbh.wv.gov\/page\/information-medication-assisted-treatment-mat-providers-west-virginia. Accessed September 25, 2025."},{"key":"10.1016\/j.amepre.2026.108508_bib0027","article-title":"Barriers and facilitators to substance use disorder treatment: an overview of systematic reviews","volume":"16","author":"Farhoudian","year":"2022","journal-title":"Subst Abuse"},{"issue":"8","key":"10.1016\/j.amepre.2026.108508_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.27418","article-title":"Pharmacy barriers to receiving buprenorphine among patients undergoing telemedicine addiction treatment","volume":"8","author":"Hendy","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.amepre.2026.108508_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.3549","article-title":"Removal of Medicaid prior authorization requirements and buprenorphine treatment for opioid use disorder","volume":"4","author":"Christine","year":"2023","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.amepre.2026.108508_bib0030","series-title":"Opioid use disorder among Medicaid enrollees: snapshot of the epidemic and state responses","author":"Donohue","year":"2019"},{"issue":"8","key":"10.1016\/j.amepre.2026.108508_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.25999","article-title":"Buprenorphine prescribing characteristics following relaxation of X-waiver training requirements","volume":"7","author":"Christine","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amepre.2026.108508_bib0032","article-title":"A multi-method spatial examination of factors associated with changes in geographic accessibility to buprenorphine providers in HEALing communities study states Kentucky, Massachusetts, and Ohio","volume":"53","author":"Shrestha","year":"2025","journal-title":"Prev Med Rep"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379726002515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379726002515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:03:24Z","timestamp":1792065804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379726002515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0749379726002515"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2026.108508","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State X-Waiver Statutes and Buprenorphine Prescriber Rates After Federal X-Waiver Elimination, 2021\u22122023","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2026.108508","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108508"}}